Tau-protein targeting compounds and associated
The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
1. A compound selected from:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound demonstrates Tau protein degradation of greater than 50% as determined in CHOK1 Tau P301 L cells treated with 1 μM of compound for 48 hours as compared to untreated cells.
3. The compound of claim 1 , wherein the compound demonstrates Tau protein degradation of less than or equal to 50% as determined in CHOK1 Tau P301 L cells treated with 1 μM of compound for 48 hours as compared to untreated cells.
4. The compound of claim 1 , wherein the compound demonstrates Tau protein degradation in an in vivo tauopathy mouse model.
5. The compound of claim 1 , wherein the compound demonstrates Tau protein degradation of seed-competent pathologic tau aggregates in vitro and in vivo.
6. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6 , wherein the composition further comprises an additional bioactive agent.
8. The pharmaceutical composition of claim 7 , wherein the additional bioactive agent is an anti-neurodegenerative agent.
9. The pharmaceutical composition of claim 7 , wherein the additional bioactive agent is a P-gp inhibitor.
10. The pharmaceutical composition of claim 9 , wherein the P-gp inhibitor is Amiodarone, Azithromycin, Captopril, Clarithromycin, Cyclosporine, Piperine, Quercetin, Quinidine, Quinine, Reserpine, Ritonavir, Tariquidar, Elacridar or Verapamil.
11. The compound of claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
20. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
21. A method of treating Alzheimer's disease in a subject comprising administering to a subject in need thereof, the compounds of claim 1 and pharmaceutically acceptable salts thereof.